Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance
Integrase Strand Transfer Inhibitors (INSTIs) are currently used as the most effective therapy in the treatment of human immunodeficiency virus (HIV) infections. Raltegravir (RAL) and Elvitegravir (EVG), the first generation of INSTIs used successfully in clinical treatment, are susceptible to the e...
Main Authors: | Clémence Richetta, Nhat Quang Tu, Olivier Delelis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/14/12/2591 |
Similar Items
-
HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
by: Pablo Ferrer, et al.
Published: (2020-09-01) -
Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
by: Thibault Mesplède, et al.
Published: (2015-07-01) -
HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
by: Emma G. Foster, et al.
Published: (2022-12-01) -
Pharmacokinetic drug interactions of integrase strand transfer inhibitors
by: Chi-Hua Lu, et al.
Published: (2021-01-01) -
A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
by: Alexa Vyain Zhao, et al.
Published: (2022-10-01)